Michela Gallagher
Company: AgeneBio
Job title: Founder & Chief Executive Officer
Seminars:
Chair Led Q&A 10:25 am
day: Day One
Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial 9:30 am
Novel therapeutic targets; hippocampal overactivity driving Alzheimer’s Disease pathology (amyloid deposition, tau progression and cortical atrophy) in patients with amnestic mild cognitive impairment Success Story: AGB101 (low dose levetiracetam) reduces hippocampal overactivity and restores task related episodic memory function in a Phase 2A study in patients with amnestic mild cognitive impairment Clinical Update: HOPE4MCI is…Read more
day: Day One